Iovance Biotherapeutics IOVA shares are trading lower on Thursday, after the company announced a $500 million proposed public offering of common stock.
Iovance Biotherapeutics is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells.
Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.
Iovance Biotherapeutics shares were trading down 11.39% at $33.75 at the time of publication on Thursday. The stock has a 52-week high of $41.49 and a 52-week low of $16.12.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
